185 related articles for article (PubMed ID: 34245333)
1. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
Hong CR; Mehta SY; Liyanage HDS; McManaway SP; Lee HH; Jaiswal JK; Bogle G; Tercel M; Pruijn FB; Wilson WR; Hicks KO
Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
3. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Hong CR; Wilson WR; Hicks KO
Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
[TBL] [Abstract][Full Text] [Related]
4. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
Hong CR; Bogle G; Wang J; Patel K; Pruijn FB; Wilson WR; Hicks KO
Front Pharmacol; 2018; 9():1013. PubMed ID: 30279659
[TBL] [Abstract][Full Text] [Related]
5. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013; 3():263. PubMed ID: 24109591
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
[TBL] [Abstract][Full Text] [Related]
7. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
Jackson-Patel V; Liu E; Bull MR; Ashoorzadeh A; Bogle G; Wolfram A; Hicks KO; Smaill JB; Patterson AV
Front Pharmacol; 2022; 13():803602. PubMed ID: 35211015
[TBL] [Abstract][Full Text] [Related]
8. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
9. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
10. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
11. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
[TBL] [Abstract][Full Text] [Related]
12. Zinc finger nuclease knock-out of NADPH:cytochrome P450 oxidoreductase (POR) in human tumor cell lines demonstrates that hypoxia-activated prodrugs differ in POR dependence.
Su J; Gu Y; Pruijn FB; Smaill JB; Patterson AV; Guise CP; Wilson WR
J Biol Chem; 2013 Dec; 288(52):37138-53. PubMed ID: 24196959
[TBL] [Abstract][Full Text] [Related]
13. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
Foehrenbacher A; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013 Dec; 3():314. PubMed ID: 24409417
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
[TBL] [Abstract][Full Text] [Related]
15. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
[TBL] [Abstract][Full Text] [Related]
16. An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.
Mao X; McManaway S; Jaiswal JK; Patel PB; Wilson WR; Hicks KO; Bogle G
PLoS Comput Biol; 2018 Oct; 14(10):e1006469. PubMed ID: 30356233
[TBL] [Abstract][Full Text] [Related]
17. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
18. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
[TBL] [Abstract][Full Text] [Related]
19. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
Guise CP; Abbattista MR; Anderson RF; Li D; Taghipouran R; Tsai A; Lee SJ; Smaill JB; Denny WA; Hay MP; Wilson WR; Hicks KO; Patterson AV
Molecules; 2020 Oct; 25(21):. PubMed ID: 33105798
[TBL] [Abstract][Full Text] [Related]
20. Engineering the
Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
